期刊文献+

高效液相色谱法分离和测定匹伐他汀钙对映体及其含量 被引量:5

HPLC separation and determination of pitavastatin calcium and its enantiomer
下载PDF
导出
摘要 目的:建立一种用手性固定相直接分离匹伐他汀钙对映体的方法并测定异构体的限量。方法:柱温25℃用α-酸性糖蛋白柱(150 mm×4.0mm,5μm),以0.03 mol·L^(-1)磷酸氢二钠溶液(用磷酸调 pH 值至6.5)-乙腈(90:10)为流动相,流速为1.0 mL·min^(-1),检测波长为245 nm。结果:α-酸性糖蛋白柱对匹伐他汀钙手性异构体有良好拆分能力,匹伐他汀钙及其异构体的分离度符合要求。结论:该方法操作简便,可用于匹伐他汀钙原料中异构体的限度控制。 Objective:To establish an HPLC method for the and its enantiomer with a chiral stationary phase. Methods:α- separation and determination of pitavastatin calcium -acid glycoprotein column was used as chiral column ( 150 mm×4.0mm,5μm) at 25 ℃ with 0. 03 mol · L^-1 sodium dihdrogenphosphate buffer - acetontrile (90: 10) as the mobile phase. The flow rate was 1.0 mL ·min^-1 and the detection wavelength was 245 nm. Results :Pitavatatin Calcium and its enantiomer were separated well on the α - acid glycoprotein column and the resolution was consistent with the requirements. Conclusion:The method is suitable for the separation of pitavastatin calcium and its enantiomer, and is valuable for the limitation control of enantiomer of pitavastatin calcium.
出处 《药物分析杂志》 CAS CSCD 北大核心 2008年第8期1333-1335,共3页 Chinese Journal of Pharmaceutical Analysis
关键词 匹伐他汀钙 对映异构体 高效液相色潜 手性固定相 pitavastatin calcium enantiomer HPLC chiral stationary phase
  • 相关文献

参考文献3

二级参考文献25

  • 1Kajinami K, Koizumi J, Ueda K, et al. Effects of NK- 104, a new hydroxymethyglutaryl-coenzyme reductase inhibitor,on low-density lipoprotein cholesterol in heterozygous familial hyperc holesterolemia. Hokuriku NK-104 study group[J].Am J Cardiol,2000,85(2) : 178 - 183.
  • 2Sone H, Takahashi A, Shimano H, et al. HMG-OoA reductase inhibitor decreases small dense low-density lipoprotein and remnanlike particle cholesterol in patients with type-2 diabetes[J ].Life Sci, 2002,71 (20) : 2403 - 2412.
  • 3Akiba T, Shibuta T, Amano Y, et al. Six-month repeated oral toxicity study of NK-104 in rats[J]. J Toxicol Sci, 1998,23(Suppl 5) :S713 - S720.
  • 4Akiba T, Shibuta T, Amano Y, et al. 28-day repeated oral toxicity study of a hypolipidemic agent, NK-104 in rats[J]. J Toxicol Sci,1998,23(Suppl 5) :S701-S711.
  • 5Suzuki M, lwasaki H, Fuj;kawa Y, et al. Synthesis and biological evalutions of quinoline-based HMG-CoA reductase inhibitors[J].Bioorg Med Chem ,2001,9(10) :2727-2743.
  • 6Morikawa S, Umetani M, Nakagawa S, et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells[J] .J Atheroscler Thromb ,2000,7(3):138-144.
  • 7Ooyen C, Zecca A, Bersino AM, et al. NK-104, a potent 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitor, decreases apolipoprotein B-100 secretion from HepG2 cells[J]. Atherosclerosis,1999,145(1) :87 - 95.
  • 8Kohno M, Shinomiya K, Abe S, et al. Inhibition of migration and proliferation of rat vascular smooth muscle cells by a new HMGCoA reductase inhibitor, pitavastatin [J]. Hypertens Res, 2002,25(2) :279-285.
  • 9Morikawa S,Takabe W, Mataki C, et al. The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells[J]. J Atherosccler Thromb ,2002,9(4) : 178 - 183.
  • 10Kitahara M, Kanaki T, Toyoda K, et al. NK 104, a newly developed HMG-CoA reductase inhibitor,suppresses neointimal thickening by inhibiting smooth muscle cell growth and fibronectin production in ballon-injured rabbit carotid artery[J].Jpn J Pharmacol, 1998,77(2) : 117 - 128.

共引文献32

同被引文献1991

引证文献5

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部